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Abstract: The development and implementation of artificial intelligence (AI) applications in health
care contexts is a concurrent research and management question. Especially for hospitals, the expec-
tations regarding improved efficiency and effectiveness by the introduction of novel AI applications
are huge. However, experiences with real-life AI use cases are still scarce. As a first step towards
structuring and comparing such experiences, this paper is presenting a comparative approach from
nine European hospitals and eleven different use cases with possible application areas and benefits
of hospital AI technologies. This is structured as a current review and opinion article from a diverse
range of researchers and health care professionals. This contributes to important improvement
options also for pandemic crises challenges, e.g., the current COVID-19 situation. The expected
advantages as well as challenges regarding data protection, privacy, or human acceptance are re-
ported. Altogether, the diversity of application cases is a core characteristic of AI applications in
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hospitals, and this requires a specific approach for successful implementation in the health care sector.
This can include specialized solutions for hospitals regarding human–computer interaction, data
management, and communication in AI implementation projects.
Keywords: COVID-19; artificial intelligence; uses cases; European hospitals; benefits
1. Introduction
Research into applications of artificial intelligence (AI) in health care and within
hospitals is a crucial area of innovation [1]. Smart health care with the support of AI
technologies, such as Machine Learning (ML), is needed due to specific challenges in the
provision of medical support in European countries as well as in the rest of the world. It is
not only the outbreak of the COVID-19 pandemic that reveals the current problems and
challenges facing European hospitals. The success in the science of medicine in the last
decades has had the effect of patients becoming older, frailer, and multi-morbid due to a
longer lifetime expectation [2].
This is accompanied by the fact that medical care and diseases are becoming increas-
ingly complex. Due to this medical complexity, medical personnel are becoming more and
more specialized, which cannot in general be fully provided for by smaller hospitals in
rural areas. Added to this is the demographic change already emerging in Europe, e.g.,
the population of over 80-year-olds in the EU27 will double from 6.1% in 2020 to 12.5% in
2060 [3]. Hence, more older people with their specific health problems will use the health
care system. In contrast to this, the number of young well-trained medical personnel is
currently decreasing and a shortage of skilled personnel, such as doctors and nurses, is
already emerging in many European nations [4].
The challenges of the simultaneous increase of older and multi-morbid patients with
complex diseases and the shortage of skilled personnel are also hampered by the increasing
economic constraints on hospitals. An increase in chronic diseases due to aging populations
and shortage of medical specialists results in resource scarcity and medical sustainability
challenges. In order not to endanger the living and health standards of the European
nations it will be necessary to develop applied AI-solutions to relieve the burden of
increased workload as well as being instrumental to deliver efficient, effective, and high-
quality health care.
Adaptability and agility at hospitals are major prerequisites in this context, and
narrowing the application of AI to optimization solely does miss the point in many cases.
By opening a wider range of actionable options, from personalized medical diagnosis and
treatment to choices in care, sourcing, and logistics areas, AI applications will provide
more important support avenues than efficiency enhancements only [5,6]. In addition,
multiple benefits regarding the ongoing COVID-19 pandemic can also be expected and
should be further explored, especially regarding data analysis and preventing unnecessary
patient contact for health care personnel in hospitals as centres of the fight against the viral
disease [7].
AI can also contribute to the fight against pandemics as COVID-19, helping hospitals
focus resources on pandemic patient’s treatments in the current as well as possible future
situations. In this sense, most AI applications are directed at contactless analysis, diagnosis,
and treatment (e.g., self-treatment and prevention), reducing the number of personal
contacts and hospital visits, therefore reducing the potential spread of COVID-19 and
other viral pandemics. AI in particular offers great potential for improving medical care
and supporting the medical staff. The state of the art and the challenges regarding AI
applications in hospitals and the health care sector are described for specific application
areas in Figure 1.
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With regards to the introduction of AI applications in hospitals, two specific questions
arise, with the answers to them as the central contributions of this paper: First, what are
the requirements and hospital setups for AI applications? To this end, the authors carried
out a survey of different European hospitals and identified relevant projects in this field.
As a result, the main fields of application of AI for hospitals are found as care, diagnosis,
and logistics. The hospitals surveyed saw the greatest medical and economical potential
in these three areas through the use of AI. Building on this, the paper outlines altogether
11 use cases in 9 hospitals across Europe, informing how AI can contribute to agility and
efficiency in hospitals, improving health care from the resource efficiency as well as the
service quality and choice side, aligned with the core hospital workflow and value adding
processes. The second question is: How can a basic structure for the different AI use cases
be established to avoid the mistake of developing isolated solutions that are difficult to
transfer across hospitals? The authors propose three basics support areas which help to
ensure a holistic approach to AI application implementation and transfer within the paper.
The paper is structured as follows: The following section is outlining the applied use
case methodology for the analysis presented. The next section is describing the specific
use case descriptions and expectations of hospitals towards AI applications. The following
section presents a discussion regarding possible benefits and challenges as well as concept
items such as human–computer interaction and medical data space concepts to overcome
the challenges posed by AI applications in the hospital context. The final section provides
an outlook towards future developments and challenges for AI applications in hospitals.
2. Use Case Methodology
The first step to identify the current challenges and areas of interest of European
hospitals was to create a survey. The survey was carried out to obtain a differentiated
view of the needs f European hospitals. Specific were quested, such as country, type,
number of pati n s nd beds, and the main health care areas. In addition, hospital decision-
mak rs identified specific areas of ap li ation and presented the focu and expected output
of the utility of AI. The following Table 1 outlines the specific setup f these ho pital
characteristics for the institutions included in the survey.
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Table 1. Included survey and case study hospitals in Europe.
Hospital Type/Inpatient per Year/Outpatient perYear/Beds 1 Main Health Area(s)
Specific Application Areas (AA)/Focus on
(F)/Expected Output (EO)
University Hospital of Bern (Switzerland) Public/6000/737,830/64 (2018) 2
The University Clinic for Obstetrics and
Gynecology of Inselspital
AA: Diagnosis
F: Fetal state assessment during labor
EO: AI-based decision support system for fetal state
assessment during labor. The solution can assist
obstetricians in accurately assessing the fetal state in
clinical practice during labor.
Kuopio University Hospital (Finland) Public/99,000/517,000/590 (2019) 3 All branches
AA: Diagnosis
F: Finding new diagnostic and treatment methods, for
coronary artery disease.
EO: An AI-based decision support system for selecting
those patients among suspected CAD who benefit from
further imaging.
Hospital of Bozen (Italy) Public/25,064/737,830/697 (2018) 4 All branches
AA: Care
F: Rheumatological diseases and diabetes
EO: An intelligent tool able to support the definition and
scheduling of the different laboratory tests, medical
examinations and hospitalization.
La Fe University Hospital (Spain) Public/45,062/148,702/1004 (2019) 5
Management of
Chronicity (Integrated Care) and Active
and Healthy Aging
AA: Care
F: Strategic initiatives on integrated care for patients with
complex chronic and/or oncological conditions
EO: An intelligent tool able to improve the management
of chronic patients and to characterize the use of
resources throughout chronic patients’ healthcare,
reducing the economic burden for hospitals.
Federico II University of Naples (Italy) Public/n.a./365,000/1000 (2019) 6
Arterial hypertension on the
cardiovascular system
AA: Care
F: Arterial hypertension with particular reference to
ischemia heart disease
EO: Development of diagnostic and therapeutic
methodologies in the field of cardiac rehabilitation;
development of remote monitoring systems
(telemedicine) for patients with high cardiovascular risk.
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(F)/Expected Output (EO)




treatment, pain medicine and
rehabilitation
AA: Care
F: Ethical, rehabilitation and preventive care
EO: Developing new tools for the treatment and
rehabilitation of musculoskeletal disorders and
other conditions.
Odense University Hospital (Denmark) Public/104,229/1,104,229/1038 (2019) 8 All branches
AA: Logistics
F: Future of health care in mind, incorporating innovative
clinical and logistical technologies.
EO: To serve as a test bed for new medical technology,
including an extensive use of robotics and AI.
Bayındır Hospital (Turkey) Private/11,284/252,995/131 (2019) 9 All branches
AA: Logistics
F: Materials management and scheduling
EO: Optimizing resource allocation and medical




10 Genetic medicine, immunology, oncology,
cardiovascular medicine and transplants
AA: Logistics//F: Care operations with materials
management and supply//EO: Digitalized, patient- and
employee-oriented organization. To minimize time spent
for the nurses on documentation and administrative
tasks to allow more time for direct patient care.
1 Data from hospital sources. Definitions might differ due to national data regulations. 2 University Hospital of Bern: http://www.frauenheilkunde.insel.ch/de/ueber-die-klinik, accessed on 2 October
2020. 3 Kuopio University Hospital: https://www.psshp.fi/web/en/organisation/operations-and-tasks, accessed on 2 October 2020. 4 Südtiroler Sanitätsbetrieb: https://www.sabes.it/de/578.asp,
accessed on 2 October 2020. 5 La Fe University Hospital: Hospital activity report, 2019. 6 Federico II University of Naples. 7 Orton Ltd. University Hospital. 8 Odense University Hospital: https:
//en.ouh.dk/about-ouh/key-figures, accessed on 2 October 2020. 9 Bayındır Hospital. 10 Universitätsklinikum Essen: https://www.uk-essen.de, accessed on 2 October 2020.
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The framework situations for the outlined AI use cases are characterized by their specific
hospital setup in a broad multitude of European hospitals. By means of surveys carried out
in the hospitals participating in this analysis, different health care personnel have provided
systematic answers to a structured questionnaire dealing with relevant aspects to the study.
The hospitals where asked to detail current practical problems in different areas, how are they
currently managing these problems, ways and mechanisms to improve in these areas by means
of AI, and relevant KPIs determining qualitative and quantitative improvements related to
the adoption of the AI application. As a result, after extracting the information from these
surveys, use cases could be drafted for the different health institutions, based on real and actual
needs and opportunities. Societies require an effective and efficient health care system and
especially hospitals as nodes in a network of actors providing high-quality services, resources
and serving patients. The following table summarizes the main expectations as stated by the
health organizations in the survey (see Table 2).
From the expectations, a total of 11 use cases in different health areas has been
envisioned. It turns out that three particular fields are of specific interest to the hospitals
surveyed: diagnosis, care and logistics.
In the field of diagnosis, clinical decisions still mostly depend on the application
of clinical practice guidelines, instead of being based on the use of automatic decision
support tools that exploit the increasing availability of medical data from molecular assays,
electronic health records, clinical and pathological images, and wearable connected sen-
sors. Nowadays, clinicians face enormous challenges in reconciling heterogeneous clinical
data and exploiting the information content to make optimal decisions when assessing
a disease or its progression, and this situation has become more evident in the midst of
the global COVID-19 pandemic. Thus, there is an urgent need to develop smart decision
support systems, which assist clinicians in making rapid and precise diagnostic decisions
through the combination of multiple data sources. AI-based methodologies for medical
diagnosis and medical decision support have gained attention in the recent years as these
systems hold promise to automate the diagnosis and triage processes, thus optimizing and
accelerating the referral process especially in urgent and critical cases. Recently, state-of-
the-art examples demonstrated that software based on AI can be used in clinical practice to
improve decision-making and to achieve fast and accurate databased diagnosis of various
pathologies. In particular, AI has been proven particularly helpful in areas where the
diagnostic information is already digitized, such as: for detection of cancers based on
molecular, genomic, and radiological data [8], making individual prognosis in psychiatry
using neuroimaging [9,10] identifying strokes from computed tomography scans [11],
assessing the risk of sudden cardiac death or other heart diseases based on electrocardio-
grams and cardiac magnetic resonance images [12,13], classifying skin lesions from skin
images [14], finding indicators of diabetic retinopathy in eye images [15], and detect pheno-
types that correlate with rare genetic diseases from patient facial photos [16]. The change in
clinical practice through and by the means of technological innovation is today decisively
enabling health care systems to face to the continuous economic, socio-demographic and
epidemiological pressures [17]. However, technological innovation, although important
and central, must be carefully examined and accompanied to ensure that it really corre-
sponds to effective social innovation. As addressed by MedTech Europe, developing AI
systems and algorithms for healthcare settings requires specific skillsets which are in short
supply, and investment in education and training of professionals involved (e.g., data
scientists, practitioners, software engineers, clinical engineers), is mandatory [18].
Healthcare 2021, 9, 961 7 of 24
Table 2. Included survey and case study hospitals in Europe.
Heath Organization Current Problems and Approach Vision on Potential Application of AI Expected Improvement—KPIs
University Hospital of Bern, Department of
Obstetrics and Gynecology
Fetal assessment based on Cardiotocography (CTG)
or electronic fetal monitoring (EFM) limitations.
Their vision is to develop a medical decision support
system, which can assist obstetricians in accurately
assessing the fetal state in clinical practice during labor.
Improvement of decision-making can improve fetal
outcomes after delivery and avoid unnecessary medical
interventions and their health implications for mother
and fetus, as well as their economic implications. The
KPIs of the AI application are:
• Fetal outcomes, measured by clinical adaptation
(APGAR score) and hypoxia (measured by arterial
pH),
• Invasive interventions for prematurely ending the
delivery process, such as instrumental delivery or
cesarean section,
• Economical costs of delivery.
Kuopio University Hospital
Currently, the diagnosis of coronary heart disease
has changed towards the non-invasive imaging,
which has led to increasing number of patients
scheduled to CCTA. Interpretation of CCTA is
affected by the image quality, experience of the
doctor and by other issues, which can in terms lead
to unnecessary repeated or additive diagnostic
imaging.
The motivation is to develop an automatic AI-based
analysis system for the coronary computed tomography
angiography (CCTA): To enhance diagnostic accuracy of
CCTA and to guide clinical decision making.
Interpretation of CCTA will be systematically guided by
the standard AI-based analysis system.
The patients need only one diagnostic method and the
workflow of the interpretation of CCTA become more
fluent. Relevant KPIs are:
• Increased number of CCTA imaging in one center,
• Improved patient convenience, safety and decreased
health care costs,
• Improved effectiveness leads to shorter waiting
times and shortened queues.
Hospital of Bozen Limitations on healthcare resources managementand chronic care pathways definition
AI tools to support the definition and scheduling of the
different laboratory tests, medical examinations and
hospitalization which affect STHA patients, personnel,
equipment and resources inside and outside the
hospital and located in multiple areas of the
geographical territory of its responsibility
Ease the management of healthcare resources with a
particular focus on rheumatological diseases and
diabetes as chronic diseases. Relevant KPIs are:
Decrease waiting time to access to scheduled medical
examinations and labor tests,
Average cost to provide the healthcare services to the
chronic care population,
Quality of the medical treatment, e.g., percentage of
re-hospitalized patients.
La Fe University Hospital
Chronic diseases (CDs) represent the major cost of
morbidity and mortality and lead to 86% of all
deaths. In Europe, these account for more than 75%
of the healthcare burden with a cost for the
economy of €700 billion per year.
AI will help to: Improve the management of chronic
conditions and multimorbidity in the face of aging
population and its implication on public health; Contain
the impact and global burden of chronic conditions,
multimorbidity and frailty on individual quality of life
and on healthcare systems; Strength the clinical
management of complex chronic conditions and
multimorbidity having a better understanding of the
individual prognosis and disease evolution, and
targeting personalized interventions.
Optimization of resources and the clinical flow of
chronic patients at Hospital. Relevant KPIs are:
Efficiency on the allocation and consumption
of resources,
Right assignment of chronic patient to care pathway,
Decrease in turnaround time,
Selection of right pathway,
Avoidable episodes of care inadequate use.
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Table 2. Cont.
Heath Organization Current Problems and Approach Vision on Potential Application of AI Expected Improvement—KPIs
Federico II University of Naples
Today CVD is the leading cause of death in Europe;
presently 47% of all deaths in Europe and 40% of all
deaths in the European Union (EU) are attributable
to CVD. This means that across Europe as a whole 4
million deaths per year currently occur due to CVD,
of which 1.9 million are in the European Union
Use of AI may help clinicians in problem solving and
patient’s management. AI process may be used to
improve process of health care management with
specific regards to resource allocation,
patient management.
Rapid assessment of correct management strategy.
Relevant KPIs are:
Improvement of timeliness in critical event treatment,
Reduction of ambulatorial visits,
Forecasting of avoidable critical conditions.
Odense University Hospital
Maintain high quality treatment for our patients in a
demographic development scenario and increasing
chronic conditions
Need to rely on AI and robots to ensure quality level
and improve security in repetitive tasks, while
alleviating staffing challenges.
Optimize handling of transports and logistics.
Relevant KIPs are:
Improve timing for transportation of patients
or samples.
Release of staffing resources to other tasks/areas. As
well as an improved working environment for staff.
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In the field of care, AI for health has shown great potential to improve healthcare
efficiency, considering the relationship between health factors, including service and man-
agement, and ICT factors that include sensors, networks, data resources, platforms, ap-
plications and solutions [19]. For the hospital facilities, AI is one of the most powerful
technologies from the perspectives of data, computing power and algorithms. Research
in Health 4.0 has been conducted in an interdisciplinary way with a diversified set of
applications and functionalities and in terms of its implementation, it has been more com-
monly found in hospitals’ information flows, especially the ones related to healthcare
treatments [20]. In this context, it is also necessary to consider and to assess the prevailing
opinions and expectations among stakeholders regarding ICT health solutions, such as the
improvement of factors that affect quality of life, quality of health care, patient’s knowledge,
monetary aspects, or data security and privacy [21]. Although the research trend in the field
of chronic care is to keep a continuous monitoring of each patient (promoting continuity
of health and social care), tools to identify chronic patients and analyze the use of health
services (care pathways) that they perform do not exist yet, and in addition there are no AI
models that facilitate the design of integrated care pathways. There is clear evidence of the
relevance of organization and management of the technological issue in the health care,
concept further reinforced on the light of recent COVID-19 pandemic. Assessment, supply,
prioritization, appropriate usage, and exploitation are indeed not a trivial duty, and the
final success of any health process is widely affected by technology management issues.
In the field of logistics, AI can be applied in the forms of optimizing ML algorithms for
scheduling and transportation planning [22–24]. This has not been extended to AI-led prog-
nosis applications at least with empirical testing. The currently existing industry standard
draws on manual processes to plan and optimize resource use. Software applications are
being widely used in hospitals for this problem area, such as ORBIS, Medico or M-KIS that
rely on an old architecture and non-intelligent, manual interaction with users. Even spe-
cialized software modules such as myMedis support the whole process of OR management
and related resource planning but still do not use AI-based technology and thus are not
able to cope with rising complexity in resource planning optimization [25–27]. It has been
reported that AI adoption by key stakeholders such as doctors remains low [28], and that
existing applications do not cater enough to the specific needs of human stakeholders that
are supposed to interact with the systems [29]. Accordingly, a focus on human–computer
interaction (HCI) spanning pre-design, design and post-design phases as well as catering
to user, system, task, and interaction characteristics [30] holds the potential to increase AI
adoption and user satisfaction [31]. While expertise in HCI has been developed in the fields
of computer science [32,33], it has not been systematically applied to the hospital context.
3. Use Cases Descriptions and Expectations
In the field of diagnosis, we propose to advance the methods that intelligently utilize
heterogeneous data from various sources and novel AI-based methods for supporting
medical diagnosis and decision making inside clinics. More specifically, we propose
to increase the utilization of AI-based methods in four selected use cases: diagnosing
coronary artery disease (CAD), assessing fetal state during labor, diagnosing epidermolysis
bullosa (a rare genetic disease) and diagnosing arrhythmias automatically. All the use
cases provide heterogeneous data, which at the same time is a challenge for the medical
experts to handle and on the other hand provide a possibility for the rise of novel AI-
based methods in supporting diagnosis and clinical decision-making. AI-based methods
also enable detection of factors in medical diagnosis that are unnoticeable for humans.
Collaboration between technical and medical experts is crucial to co-create such tools to
be used in clinics that are highly acceptable, highly deployed, and provide real value for
patients, doctors and societies.
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3.1. Use Case 1: Coronary Artery Disease Diagnosis
Among all routinely available diagnostic tests, coronary CT angiography (CCTA) has
the highest sensitivity (95–99%) for detection of coronary artery disease (CAD), with a
specificity of 64–83%, and it has recently set up as the first-hand diagnostic tool for stabile
chest pain. However, after CCTA there are still several patients for whom the diagnosis and
reason for symptoms remains unclear and further imaging studies (myocardial perfusion
and/or invasive coronary angiography) are needed to decide the best way of the treatment.
Training a ML algorithm to recognize those cases for whom further imaging is likely
to provide essential information among the unclear cases with suspected CAD would
improve the cost-efficiency and logistic of the diagnosis of chest pain patients. In other
words, the aim would be to develop a tool for evaluating the risk of the patient to have
prognostic CAD for customized clinical decision-making. The number of the patients with
suspected CAD transmitted to hospital for diagnostic imaging is likely to grow in the future
worldwide due to recently published clinical guidelines emphasizing the use of CCTA. For
the study, a number of contemporary CCTA studies imaged and essential clinical data (age,
sex, cardiovascular risk factors and medication) could be used to train a machine-learning
algorithm such as Disease State Index (DSI), which is a method to quantify the probability
to belonging to a certain disease population, originally developed to support clinicians in
diagnosing Alzheimer’s Disease [34].
3.2. Use Case 2: AI Based Automatic Arrhythmia Analysis
Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated
with significant morbidity and adverse outcomes (stroke, heart failure, death). Overall,
AF is associated with five-fold greater risk of stroke. Anticoagulation therapy has been
demonstrated to reduce AF-related stroke risk significantly. Paroxysmal AF (PAF) is a self-
terminating recurrent form of AF. The diagnosis of PAF is often tricky since PAF episodes
can be short in duration, asymptomatic and the episode incidence can be low. It is estimated
that the stroke causes total costs of EUR 45 billion/year across Europe. In European
countries, 1.5 million peoples are diagnosed with stroke every year, 9 million are living
with stroke and it is responsible for 9% (0.4 million) of all deaths in EU [2]. Cryptogenic
stroke (CS) and transient Ischemic Attack (TIA) patients and cardiac surgery patients are
the three most clinically significant patient groups where PAF is often underdiagnosed. In
this use case, state of the art AI-based arrhythmia analysis algorithms are developed for
PAF-screening in patients with TIA or cryptogenic stroke and detection of post-operative
atrial fibrillation in cardiac surgery patients. AI-based automatic arrhythmia analysis
implemented in wearable sensors enables longer monitoring time with improved patient
usability and still requires minimal effort from healthcare professionals. Developing novel,
AI-based non-invasive methods for PAF screening, using simple wearable ECG or PPG
measurement would lead to increasing rate of PAF diagnosis in cardiac surgery, CS and TIA
patients. These monitoring methods will be easily exploitable and inexpensive. The timely
diagnosis of PAF has an important impact since anticoagulation may save the patient’s life
or prevent stroke-related disabilities such as paralysis, aphasia and chronic pain. There is a
high-cost saving potential, since one prevented stroke can save EUR 20,000 of direct medical
costs and more than EUR 100,000 of indirect costs (disability-adjusted life years lost).
3.3. Use Case 3: Fetal State Assessment during Labour
Cardiotocography (CTG), also known as electronic fetal monitoring (EFM), is used
for fetal assessment before and during labour and largely replaced the use of intermittent
heart rate auscultation. Visual interpretation of CTG traces is characterized today by a
great inter- and intra-observer variability with low specificity. EFM has been shown to
lead to unnecessary medical interventions such as caesarean section and vaginal-operative
deliveries, with the associated health consequences and economic costs. The low speci-
ficity for identifying fetal hypoxia can be partially interpreted in the context of observer
variability. CTG recording is widely performed for fetal assessment during delivery and
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has become routine in most hospitals worldwide. A software program connected to the
electrodes of the electronic fetal monitoring system (EFM) registers fetal and maternal data
such as fetal heart rate and its variations, maternal heart rate, uterine contractions and
fetal movements. Currently, the most specific available CTG interpretation system is the
FIGO (Fédération Internationale de Gynécologie et d’Obstétrique) classification, which is
most commonly used worldwide [35]. Fetal outcomes after delivery are being measured
by assessing following two parameters: (1) arterial pH directly after birth (blood from the
umbilical cord); (2) APGAR score assessment at 1, 5 and 10 min after delivery. This not only
offers information about the fetal state, but also gives observer (obstetricians and midwives)
direct feedback about previous CTG interpretation during delivery as well as prediction
of fetal hypoxia/acidosis. An arterial pH under 7.15 is considered to be pathologic and
is a direct indicator of fetal hypoxia. An APGAR score under 7, measured 5 min after
delivery is also considered to be pathologic. APGAR as scoring system based on five fetal
features—appearance, pulse, grimace, activity and respiration—providing information
about the status of the new-born after delivery [36]. Considering the problematic of ob-
server variability, four scenarios are possible when CTG interpretation is performed by
obstetricians or midwives: (1) normal CTG, normal outcomes (pH/APGAR); (2) patho-
logical CTG, normal outcomes (pH/APGAR); (3) normal CTG, pathological outcomes
(pH/APGAR); (4) pathological CTG, pathological outcomes (pH/APGAR). By introducing
AI interpretation, the purpose is to improve scenario 2 and 3, which will in most cases lead
to avoidance of surgical interventions, since the main problem of CTG is specificity; or
to performing interventions at moments where one would otherwise refrain from doing
so (version 3). The AI system could provide feedback when fetal asphyxia is expected
(pH < 7.15 or APGAR at 5 min < 7), as well as warnings, if applicable. The proposed AI
(or ensemble of several AI instances) would help in removing the existing great inter- and
intra-observer variability and would lead to a direct and positive impact on effectiveness
and efficiency through: (1) decrease of unnecessary caesarean section and instrumental
delivery; (2) increase of specificity for identifying fetal hypoxia; (3) decrease of unnecessary
health costs derived from unnecessary surgical procedures.
3.4. Use Case 4: Diagnosis in Epidermolysis Bullosa, a Rare Genetic Disease
In Europe, a disease is considered rare when it affects less than 1 in 2000 people. There
are more than 7000 rare diseases (RDs) worldwide, about 80% of them has a genetic origin
and approximately 75% affect children. RDs are estimated to affect 350 million people
globally [37]. In better-resourced countries, correct diagnosis of rare genetic diseases takes
on average between 5.5 and 7.5 years. In Europe and United States, nearly half of the first
diagnoses are only partially correct. The deployment of effective diagnostic procedures is
hampered by the underestimation of the true disease frequency (owing to the lack of RDs’
awareness) and by an insufficient knowledge of the disease pathophysiology and natural
history combined with the paucity of validated disease-specific biomarkers. Epidermolysis
bullosa (EB) is a group of inherited, genetic diseases in which the skin (and the mucous
membranes) is very fragile and forms severe, chronic blisters and lesions after even minor
frictions or trauma. This rare genetic disorder affects all genders, ethnic and racial groups
and determines either an early death or a long-term debilitating and life-threatening
condition, since the severe blistering and associated scarring and deformities result in poor
quality of life and reduce life expectancy. In the world there are about 500,000 persons
affected by this disease and 36,000 in the European Union (EU). EB can be classified into
four major subtypes, such as dystrophic EB (DEB), junctional EB (JEB), EB simplex (EBS),
and Kindler Syndrome depending on the gene mutations and the level of skin cleavage [38].
Within the subtypes, EB has different severity levels and clinical manifestations. There is
an urgent need to develop efficient methods for the early diagnosis of the EB subtype, the
prediction of the disease progression and, consequently, the selection of individualized,
precision therapeutic strategies. In this endeavour, “omics technologies”, as genomic
analysis by means of next generation sequencing (NGS), have recently found applications in
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the diagnosis, molecular subtyping, and follow-up prediction of EB. Information retrieved
from these technologies represents a substantial increase in the amount of data that can
be used to support EB patients, provided that advanced computational methods are
available for their integrative and combinatorial analysis. In this use case, state-of-the-art
AI algorithms are developed and applied for supporting early diagnosis, sub-classification,
and therapeutic stratification of EB, as an example of rare genetic disease. In particular,
AI-based methods will be applied to the integrative analysis of biological (genomics,
molecular, immunological, and images) and epidemiological (medical records) data with
the aim to: (1) support disease and disease subtype diagnosis; (2) identify distinctive
features (genomic lesions, proteins, and immunological states) associated to disease severity
(biomarkers) for the prediction of disease progression; (3) detect molecular signatures for
guiding patient stratification for novel means of treatment (precision therapeutics). ML
algorithms can be trained to integrate phenotypic and clinical data for the prioritization of
disease-related genes and mutations, for the prediction of the pathogenicity and disease
clinical relevance of genetic variants, and for the identification of pathogenic variant
combinations. Furthermore, AI-based methods could be used for disease comprehension
and therapeutic target selection by unravelling the affected genetic and molecular players
and pathways. AI and ML can be applied to detect anomalies in gene expression and to
correlate transcriptional patterns with molecular mechanisms and clinical phenotypes, to
learn low frequency patterns, and to deliver automated class attribution [37]. Results from
these analyzes would facilitate the recommendation of optimal treatment approaches and
the identification of reliable biomarkers of normal versus pathogenic states and of response
to therapeutics interventions. AI methods focusing on removing the existing limitations
in the correct diagnosis of EB subtypes and in the prediction of the clinical course of EB
patients might achieve at least the same average accuracy as medical doctors following
the latest consensus reclassification of inherited EB. The AI-based integrative analysis of
biological and medical data will have a direct and positive impact on effectiveness and
efficiency through: (1) decrease in the time needed for the diagnosis of the correct EB
subtype and the stratification of the patient for the most effective therapeutic treatment;
(2) increase in the number and efficacy of diagnostic and prognostic biomarker; (3) increase
in the efficacy of selection criteria to identify patients who will benefit from ex vivo gene
therapy; (4) decrease of unnecessary life-threatening conditions and health costs derived
from delayed diagnosis and treatment administration.
In the field of care, AI will be applied in four other use cases: to improve the manage-
ment and decision support process, specifically in the chronic care pathway and resources
characterization, simulation of demand and prognosis, adverse events identification and
prevention, chronic resources management support tool and monitoring of the recovery
process. Novel innovative tools for simulation and prognosis would become available,
projecting the demand in terms of health resources for a given characteristic population
in a territory, considering temporary projections of frailty condition of population and
patients. As for recovery monitoring, contactless determination of vital signs will suppose
an advanced functional aspect by monitoring of all patients and not only critical cases.
Patients will benefit from reduced restrictions due to cables and devices. In addition, there
is a time saving for nursing staff, as they do not have to put the devices on the patient and
disinfect them. Regarding prevention of adverse critical conditions, the proposed approach
relies on the analysis of the entire temporal series of vital signs by means of deep neural
networks and hybrid approaches.
3.5. Use Case 5: AI Chronic Management and Decision Support Engine
According to the data of the World Health Organization (WHO), respiratory diseases
together with cardiovascular diseases are leading causes of death and disability in the
world. Considering this premise, the use of case will focus on the analysis of data from
chronic patients diagnosed with one of these four common pathologies: COPD, asthma,
coronary heart disease (e.g., heart attack) and cerebrovascular disease (e.g., stroke). The
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objective would be to apply AI in the clinical context of chronic care to characterize the
pathways and resources used, as well as anticipate the demand of resources in order to
optimize the economic costs. ML could be then used to analyze data of patients related
to clinical parameters (e.g., laboratory tests), use of resources (e.g., hospitalizations), so-
ciodemographic data (e.g., age, gender), and quality of life, among others. The AI engine
would be able to support two analysis processes: the chronic care pathway and resources
characterization (stratify patients by degree of frailty and map pathways), and resources
demand simulation and prognosis (according to each pathway/patient strata).
3.6. Use Case 6: Chronic Resources Management Support Tool
As stated by the surveyed hospitals, efficient and effective scheduling of the resources
is a challenge for most hospitals. Possible resources to be scheduled are patients’ beds,
material, medicament and assistance kit, medical equipment (e.g., diagnostic machines)
or operating theatres. The goal would be to automatically schedule the usage of the
considered resources as well as to measure and improve quantitative KPIs considered
relevant for the most significant hospital metrics, e.g., cost, service level, delivery time,
resource utilization, etc. To achieve this objective it is necessary to carry out the following
activities: (1) translating hospital needs, often presented in a medical language, in technical
concepts; (2) define the scheduling problem to be tackled by the intelligent algorithm
and input data; (3) development an intelligent algorithm to automatically schedule the
usage of resources and to measure quantitative KPIs over time; (4) test and validation of
the intelligent algorithm using real datasets with the aim to fine-tune the procedures and
selection rules implemented in the algorithm; (5) continuous learning of the intelligent
algorithm by its utilization, performances and evolution of the surrounding environment.
3.7. Use Case 7: Adverse Events Identification and Prevention
Clinicians require support in the identification and prevention of adverse clinical
conditions (ACC), as well as in identifying the main related care pathways. The technology
could support the clinician in the automatic identification of ACC, such as a reaction to
a new drug assumed by the patient after a change of her/his treatment plan. The AI
tools could analyze data caught by vital signs monitoring systems, such as heart rate,
pressure, body temperature and other data coming from the patient, such as information
inferred by dialog systems based on natural language processing that would periodically
interact with the patient to identify specific symptoms. Additionally, the tools would
be able to support clinical staff in case a change within the care pathway is needed due.
The objective would be to identify and forecast ACC for patients with non-communicable
chronic diseases, particularly referring to cardiovascular diseases, by using AI. Models and
tools for the automatic identification of ACC would be preliminarily realized adopting
retrospective data and classic ML algorithms using current guidelines on the management
of diseases of interest. Such models and tools, however, could be continuously improved,
following a continuous learning approach. Successively, the prevention of ACC could be
attempted by advanced classification systems, based on a combination of deep learning
and reinforcement learning approaches that will analyze time series data concerning the
patient condition evolution at different stages of the care pathway.
3.8. Use Case 8: Monitoring of the Recovery Process
Monitoring of the recovery process is a key hospital process. In order to achieve a high,
continuous quality, vital parameters have to be monitored constantly. Vital parameters
such as the heart rate or the respiration rate are key indicators for the current health status,
urgent emergencies and the recovery process. Especially, persons with chronic diseases
benefit from a continuous monitoring. In areas such as operation theatres or ICUs, there is a
high coverage, whereas in normal wards or floors there is little to no coverage. The objective
would be to remote determination of vital parameters such as heart rate and respiration rate
for an improved recovery monitoring in a patient friendly method especially for chronic
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diseases. This could be realized by optical sensors with remote working mode and AI
algorithms such as CNNs, BNNs or adaptive optical flow. To achieve the objective it is
necessary to carry out the following activities: (1) identifying of optimal positioning of
optical sensors within the hospital; (2) analysis of algorithms of remote vital parameter
determination in clinical environments; (3) transfer and implementation of algorithms to
the clinical setting; (4) evaluation of algorithms in clinical setting by means of reference
systems, which would stayed synchronized; (5) interface protocol for transmission of vital
parameters to central processing unit in the hospital. It should be guaranteed that only this
meta data are transferred but not the raw data, thus protecting the privacy of the patients.
In the field of logistics, AI can be implemented for example in three different use cases
as described below. The main focus is the optimization of resource use. It is expected that
AI will help to better predict material consumption and needs in the whole process. Besides
material consumption, transport planning is a further focus point in the field of logistics.
3.9. Use Case 9: Material Consumption Recognition and Prognosis
Currently, in the University Hospital in Essen as well as many other hospitals in
Europe the documentation of used materials with hospital patients is a non-digital paper-
pencil process consuming a lot of human work time. Therefore, digital improvements
regarding automated capture system for material consumption are a prominent request in
hospitals and addressed in this use case. Together with an industry partner an innovative
care trolley is developed with a camera system and the complementary AI-based software
using ML to recognize the consumed objects with patient processes automatically. User
interaction can be implemented according to current state-of-the-art concepts. It will
provide a data recognition and prognosis tool relating actual material consumption to
patient cases and therefore enabling a bottom-up planning and prognosis for optimized
procurement and logistics in hospitals.
3.10. Use Case 10: Optimization of Human-Robot Teams in Hospital Logistics Operations
Odense’s University Hospital (OUH) will benefit from a reactive AI-based resource
management and scheduling system for material transport logistic operations. The main
goal is to improve upon current task management systems with the inclusion of an AI-
driven optimized scheduler that will be able to oversee all the available robots and to
plan, schedule and assign tasks to the relevant hospital workforce, mainly logistic robots
but also employees. The proposed task management software will have several functions
and therefore will contain several different conceptual elements: (1) an automated task-
generation system, based on Reinforcement Learning (RL) algorithm, that analyzes the
relationship between room use and materials requirements to predict what will be needed
where and when based on past experience; (2) a scheduling element that knows what
transport resources are available to it, their status and where they are; and can create
an optimal schedule out of transport requests generated from user input or the task
generation above; (3) a reactive planning element that will rework the schedule regularly,
e.g., either every hour or when new on-demand transport requests are received; (4) a
transport optimizing element that analyzes the efficiency of the transport and adjusts
scheduling parameters to produce maximal transport for minimal energy use and minimal
task requests to humans; (5) a route generator element that creates efficient routes for the
robots and sends these to robots with their new tasks, in accordance with the schedule,
coupled with a route status analyzer which takes input from sensors on the robots and
around the hospital to determine the location of any blockages; (6) A sensory data analyzer
that can use incoming data from various infrastructure sources to inform the decision-
making elements, e.g., use of elevator position to inform the route generator or use of smart
cameras that can measure room occupancy for the task generator; (7) A representation of
(a) task criticality, i.e., planned, urgent and critical in emergency situations, (b) the current
status of the material flow, (c) the robots (name, capabilities, location, current task and
status) and (d) item transport requests (also available in a form readable by humans);
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(8) and a supervision element that will be utilized to identify and criticize any suboptimal
decisions made by the scheduler and provide feedback that will be used as input for
a reinforcement learning sub-component. Task and material flow reports collected and
shared by the hospital service and logistics departments of OUH, currently exceeding
555,000 entries describing various material flow logistic cases, i.e., transfer of medication,
healthcare equipment and samples, will provide a variety of types of inputs and tasks. The
system could automatically obtain information from various hospital software sources,
e.g., human workforce positions provided by the proposed event-based messaging system
by updating and adapting the current emergency messaging solution elevator status and
sensors in the hospital.
3.11. Use Case 11: Co-Development and Evaluation
Bayındır Hospital Söğütözü in Ankara is one of the three high-capacity hospitals that
belongs to Bayındır Healthcare Group. Bayındır Healthcare Group have three hospitals,
one medical center and seven dental clinics. All healthcare facilities material management
system can be centrally monitored and controlled. This provides an additional opportunity
to study the impact of planned AI implementations over multi-location inventory systems.
The hospital has specific experiences and requirements regarding healthcare logistics. It has
an existing barcode scanning system for collecting healthcare and inventory information
that aggregates centrally for the planning the availability of medical supplies and logistics
management. However, the hospital may still benefit from a new picture recognition and
AI-based system in terms of time savings, reductions in human error, and an increase the
safety by reducing the contact between the healthcare staff and patients. Furthermore,
material management and operation room scheduling are highly interrelated in practice.
Using the OR schedules to trigger the purchase of perioperative materials is expected to
further reduce inventory costs and increase operational efficiency compared to indepen-
dent material management systems [39]. In a comparison to standalone applications of
automated inventory tracking, predictive logistics, and cognitive automation, an additional
understanding of the impact of integrated AI applications on healthcare logistics operations
will bring several challenges, including data storage and management, data exchange,
security and privacy, and integrated decision-making.
4. Discussion: Benefits and Challenges for AI in Hospitals
The specific benefits and data as well as AI application challenges are presented and
discussed in this section, based on the outlined case studies and additionally directed
towards the contribution against pandemic situations, such as COVID-19.
The use cases presented in Table 3 are distinguished by specific aspects often related
to the area of interest, e.g., diagnosis, care, treatment, logistics or rehabilitation, or to the
targeted goals, e.g., increase the efficiency of a certain health care process, improve its qual-
ity, or increase the service level. However, the detailed description of the aforementioned
case studies suggests how all the involved hospitals are affected by common challenges
and potential barriers to the adoption of AI to their healthcare processes on regular basis.
In particular, it is possible to define three main issues which should be properly managed
to ensure an efficient and effective adoption of AI tools and techniques in the healthcare
delivery processes which distinguish European hospitals. The first aspect to be considered
is the human acceptance and the real adoption of AI solutions in hospitals. The resistance to
automated and partially obscure tools which offer assistance in several healthcare services
is a major obstacle to overcome. Leveraging such tools in traditional diagnosis, care and
treatment processes is useful but often distinguished by a low level of trust, in particular
by doctors and medical personnel. Furthermore, the usage of such AI solutions should not
increase the complexity or time required to complete certain medical process, therefore
offering an adequate and well-designed interaction with human adopters. The second
challenge to be tackled to foster the adoption of AI in European hospitals is the proper
management of medical data. This information is distinguished by some features which
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make their storage and usage much more sensitive than other data typically collected in
digital environments.
However, as COVID-19 dramatically revealed, the value beyond medical data is huge.
In particular, the opportunity to systematically collect data concerning the patient con-
ditions, made diagnosis, performed treatments and defined care offer to the hospitals of
the future the chance to significantly increase the efficacy and efficiency of the healthcare
services delivered. The last area involved by AI structural adoption in European hospitals
deals with technology selection and ethics. The former includes the complex and inter-
related process of selecting a novel technology for its adoption in healthcare services, as
represented by the solutions based on AI algorithms. The assessment of the most appropri-
ate AI based technology to be adopted to ease diagnosis, treatment or care activities is a
complex and distinguished by uncertain and multiple feasible outcomes with different and
contrasting scenarios. The latter deals with the ethical aspects involved in the adoption of
AI tools and techniques, from machine based medical decision to personalized treatments,
from sharing of personal health data to acceptance of robot medical personnel. Finally,
a latter aspect concerning the challenges of adopting AI in hospitals necessarily has to
be mentioned, e.g., the appropriate involvement of adequate stakeholders. Indeed, this
last issue is of fundamental importance to ensure the real usage of AI-based solutions in
daily hospital activities by doctors, acceptance of renovated treatments and procedures by
patients as well as commitment by local administrators to this modern form of health care
assistance. Therefore, the process of stakeholder commitment is of paramount importance
and should be adequately planned and implemented. Considering all the abovementioned
challenges and potential obstacles, the following paragraphs propose possible solutions to
overcome these difficulties, to ensure the adoption of AI solutions in European hospitals
and maximizing the efficacy of the innovation provided. In particular, the proposed actions
are grouped into three categories, human–computer interaction, medical data space, and
guidebook and ethics. The linkage between these transversal activities with the application
areas proposed in the manuscript is presented in the following Figure 2.
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Table 3. AI Use Cases, AI Methods and Outcomes.
Use Case Objectives AI Method Data Available Defined Outcomes Contributions againstPandemic Situations
Diagnosis
(1) MDS for Coronary Artery
Disease (CAD) diagnosis
The aim of this study is to train a
ML algorithm to distinguish
patients with suspected CAD to
those who benefit from further
imaging studies and to those who
don’t. In other words, to evaluate
the risk of the patient to have
prognostic CAD for customized
clinical decision-making.
Disease State Index (DSI), which
is a method to quantify the
probability to belonging to a
certain disease population,
originally developed to support
clinicians in diagnosing
Alzheimer’s Disease [34]. It is
designed to be ‘disease-agnostic’,
so that it can be used equally well
for other diseases, provided that
data are available.
For the study, a number of
contemporary CCTA studies
imaged in Kuopio University
Hospital (KUH) as well as ECG,
myocardial perfusion, invasive
coronary angiography imaging
and essential clinical data (age,
sex and other demographic data,
medical history, cardiovascular
risk factors and medication) are
gathered from existing clinical
databases in KUH.




Reduction of visits to the
hospital, which increases the
patient and personnel safety.
Diagnosis
(2) AI based automatic
arrhythmia analysis
In this use case, state-of-the-art
artificial intelligence (AI) based
arrhythmia analysis algorithms
are developed and integrated
into wearable sensors.








are developed and utilized to
atrial fibrillation (AF) screening
in patients with transient
ischemic attack (TIA) or
cryptogenic stroke (CS) and
detection of post-operative atrial
fibrillation in cardiac surgery
patients. Used methods: neural
networks, deep learning, ML.
6000 24 h Holter recordings with
arrhythmia annotations.
Wearable sensor database: 700
patients (300 patients with AF
episodes) with wearable sensors.
New: TIA/CS database is
collected: 48h home monitoring
of simultaneous wearable PPG
and ECG-recordings from 100
TIA/CS patients.
Developed AF-screening solution
will enable long arrythmia
monitoring time and increased
rate of AF diagnosis. Wearable
sensors offer improved patient
usability and AI assisted
arrythmia diagnosis requires
minimal effort from healthcare
professionals; AF diagnosis has
important impact to patient itself,
since anticoagulation may save
the patient’s life (prevent
cardioembolic stroke). Cost
saving potential: one prevented
stroke can save 120,000€
to society.
Reduction of visits to the hospital,
which increases the patient safety.





(3) Medical decision support
system for fetal assessment
during labor
Improving fetal assessment with
accurate prediction of fetal
hypoxia and reduction of
caesarean and instrumental
delivery rates. Develop an
AI-powered clinical decision
support system.
Ensemble methods (e.g., stacking
and blending) combining
Explainable AI (aka XAI), neural
networks (e.g., CNN and RNN),
and gradient boosting techniques
(e.g., XGBoost)
The maternity ward of the
Department for Obstetrics and
Gynecology in the University
Hospital of Bern will provide a
dataset of cardiotocographic
(CTG) recordings. It includes
physiological data such as
maternal heart rate, fetal heart
rate, contraction strength. The
dataset is labelled by MDs.
The AI will focus on removing
the existing great inter- and
intra-observer variability while
achieving at least the same
average accuracy as medical
doctors following the “Updated
2015 FIGO Intrapartum Fetal
Monitoring Guidelines”. The
integration of our AI-powered
system should lead to a direct
and positive impact on
effectiveness and efficiency.
Assisting personnel in diagnosis
with AI in a situation where there
are not enough experienced
personnel available due to
the tpandemic.
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Table 3. Cont.
Use Case Objectives AI Method Data Available Defined Outcomes Contributions againstPandemic Situations
Diagnosis
(4) Diagnosis in Epidermolysis
bullosa, a rare genetic disease
To support disease prediction






to identify genomic lesions,
proteins and immune-logical
states associated (biomarkers).
ML algorithms will be trained to
integrate phenotypic and clinical
data to improve accurate
prediction of progress of
Epidermolysis bullosa. AI-based
methods will also be used for
disease comprehension and
therapeutic target selection by
unravelling the affected genetic
and molecular players
and pathways.
This use case will exploit data,
competencies, and facilities of the
Modena EB-Hub, the center for
diagnosis, research, assistance
and development of innovative
therapies created in January 2020
at the General Hospital
of Modena.
Definition of AI-based decision
support systems to expedite
diagnosis, correct misdiagnosis,
diagnose previously
undiagnosed, and stratify EB
patients for advance therapeutic
intervention through the
integrative analysis of clinical
phenotypes and patient health
records, genetic information,
molecular levels, biochemical
fingerprints and patient images.
Assisting doctors’ in the
diagnostic process during the
pandemic, when the resources to
be used for diagnosis is limited.
Maintaining normal procedures
of diagnosing other health
problems during the pandemic.
Care




AI techniques applied to analyze
the pathways of chronic care
patients providing simulation
and prediction capacities about





forest; decision trees). AI
adjustment to chronic care
attention, prototype testing,
application evaluation (KPI).
Historical clinical records for
patients with chronic diseases.
Data about care plans and use of
hospital services and resources
(pathways) made by this group
of patients based on degree of
frailty. Macro parameters from
population (estimate
demand/prognosis)
AI agent and tool for
dimensioning demand of
resources, including prognosis
and simulation, both at




Reduction of the transmission
risks by being able to re-organize





Identification and prevention of
critical conditions: Analysis of
vital signs, automatic recognition
of symptoms (e.g., skin rash,
mood change) and direct
interaction with patients.
Machine Learning Techniques




care, prototype, evaluation (KPI).
Test of algorithms in hospital of
Bozen with either live settings or
retrospective data. Retrospective
data as heart rate, respiration
rate, oxygen saturation and blood
pressure. Moreover, general data
such as age, sex, weight, height
and other diseases.
AI tool for critical conditions
identification and prevention
along the chronic care pathway
Control of patients with
COVID-19 confined to their
homes, before variations in their
critical conditions.
Increase in patient and family
safety, especially in patients with




An intelligent algorithm is





on chronic care, prototype testing,
validation through KPI.
Hospital models of processes for
resource utilization. Information:




Scheduling planning tool for
optimal management of hospital
care resources for patients with
chronic diseases.
Reduction the transmission risks.




(8) Monitoring of the
recovery process
Remote determination of vital
parameters such as heart rate and
respiration rate for an improved
recovery monitoring.
Methods in the Area of computer
vision and ML i.e., CNN, BNN,
adaptive optical flow, SVM etc.
Recordings from lab situations
available; more data will be
generated within the Fraunhofer
InHaus-Centre, Test of
algorithms in hospital of Bozen
Software for vital parameters.




Reduction the transmission risks
in professionals by reducing
contact with monitored admitted
patients with COVID-19.
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Table 3. Cont.




Develop an automatic material
documentation on the care
wagon or the material store in the
nursing ward based on computer
vision. A material consumption
prognoses is developed with the
derived data.
ML (computer vision, CNN):
Used materials are matched with
patient cases and their diagnoses
and treatments. Thus, it is known
which and how many materials
are needed by the individual
patient cases.
- Material lists
- Master and movement data of
the materials (order history)
- Demographic patient data
(gender, age, weight, etc.)
- Patient treatment history
- Automatic stock updates for






- Specified case cost calculation
- Higher planning reliability for
material orders
- Immediate reaction to
material shortage
- Improved forecasting for
pandemic related
uncertanities
- Dynamic management of
limited material (such as
masks, protective visors and






Optimize the internal logistics
operations of the hospital by
considering both manual and
automatic transport in a resource
management and scheduling
framework. Generate
recommendations for how to
improve manual and robotic





- Data (sensor data, operational
data) from robots operating at
the hospital
- Data from the hospitals
material management system
- Generating data from current
hospital sensor infrastructure
- Knowledge about areas that
are frequented by visitors or
patients probably infected
with COVID-19
- Status reports for certain
characteristics of automated




- Better understanding of the
events leading up to an
incident report (e.g., materials
arrived late, or robot stopped
unexpectedly)
- Facilitate future integration of
robotic solutions in hospitals
- Automatic avoidance of
infections areas (e.g., areas
frequented by visitors)
- Decreasing transmission risks
to healthcare providers by
minimizing the
patient contact.
- Optimal management of






Integration of optimization of





- Master and movement data of
the materials
- Demographic patient data
- Patient treatment database
- Availability of
healthcare resources
- Adaption routines and
experiences, e.g., comparison
of material recognition with
barcode system (already
existing, comparative case)
- Management of resources in
multi-location setting
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Human–Computer-Interaction: Despite progress in the field of health care data analytics,
resulting in more and more prototypes and technical advancement, actual adoption by key
stakeholders such as doctors remains low [28,29]. This aspect will rise in relevance when
the respective systems increase in intelligence and analytical capability. Accordingly, an
increased focus on human–computer interaction spanning pre-design, design and post-
design phases as well as catering to user, system, task and interaction characteristics [30]
holds the potential to increase AI adoption and user satisfaction in clinical practice [31].
Medical Data Space: In addition, data connections in a Medical Data Space (MDS)
with distributed AI applications will help to share resources and to support specially
and severely affected regions and hospitals. In additions, overall data transparency and
analysis will help to fight virus outbreaks earlier through faster detection and containment
options due to AI analysis. The Medical Data Space (MDS) is a specialization of the
International Data Space (IDS), which provides a trustworthy, secure and cross-domain
data space allowing to build an economy of data between companies of all domains and
sizes. IDS was the result of R&D activities in 2015 and is now actively promoted through
the Industrial Data Space Association. It is in cooperation with the OPC foundation, the
FIWARE foundation and the Industrial Value Chain Initiative and the Platform Industry 4.0.
The IDS and thus the MDS define an architecture of data providers and consumers, which
are linked through connectors forming the data space. The architecture is defined in the IDS
document describing the layers of the architecture model which in turn describe the key
components necessary to realize a data space [40]. The first prototype has been presented in
2018 at the Hannover fair. The MDS concept targets the connectivity of local data spaces in
hospitals for analytics and the application of AI-based algorithms for research or hospital
internal use. Therefore, special services are necessary to not only store and manage the
transfer of medical data securely and maintaining the sovereignty of the data owner, but
it must additionally conform to requirements on anonymity and protection of personal
medical data sets. Here, the element of value-added services for the data space becomes
relevant enabling pseudonymization and anonymization features in the process.
Medical data of patients is a highly sensitive and therefore regulated asset which
requires handling in a secure and protected environment. The Medical Data Space (MDS)
builds upon the international data space to deliver a secured, controlled data storage and
processing environment to build an economy of data between providers and consumers
retaining sovereignty and control. The MDS extends this to address the additional medical
constraints. They key concept in MDS is the trusted connector which links both parties and
enforces the security and privacy policies defined. In addition to access management the
MDS architecture introduces data-processing services (data-apps) which can preprocess
data before or after transfer. As AI-driven smart hospitals rely basically on data targets
the connectivity of local data spaces in hospitals for analytics and the application of
AI-based algorithms for research or hospital internal will be used. Therefore, special
services are necessary to not only store and manage the transfer of medical data securely
and maintaining the sovereignty of the data owner, but it must additionally conform
to requirements on anonymity and protection of personal medical data sets. Here the
element of value-added services (data-apps) for the data space becomes relevant enabling
specifically pseudonymization and anonymization features in the process. In future works,
we plan to demonstrate that medical data space technology can provide the foundation for
the development and deployment of novel AI and data management data-apps. Specifically,
a pilot program for the analysis and management of in-hospital cardiac patient intervention
treatment with the goal of understanding and analyzing several key factors that impact
the ability and capacity of a hospital to provide treatment. The location for this future
installation will be the Evaggelismos Hospital in Athens.
Guidebook and Ethics: There is clear evidence of the relevance of organization and
management of the technological issue in the health care, concept further reinforced on the
light of recent COVID-19 pandemic [41]. Assessment, supply, prioritization, appropriate
usage and exploitation are indeed not trivial duties, and the final success of any health
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process is widely affected by technology management issues. In the modern re-setting
of health-care delivery via technology innovation, data driven management, health tech-
nology assessment, clinical practice guidelines as well as medical leadership are the main
topics that have to be addressed [42]. Knowledge management and technology innovation
with their continuously growing potentiality can indeed transversally represent the answer
to the demand of efficacy and efficiency of the system. Furthermore, great expectations are
placed in information and communication technologies (ICT) with their contribution in the
development of eHealth and closely in AI with its paramount applications in the various
sectors of medical practice and public health. The change in clinical practice through and
by means of the injection of technological innovation is today decisive to make the health
and care systems able to face to the continuous economic, socio-demographic and epi-
demiological pressures [17]. However, technological innovation, although important and
central, must be carefully examined and accompanied to ensure that it really corresponds to
effective social innovation [43]. Furthermore, as really recently underlined by a joint report
of EIT Health and McKinsey [44]. AI has indeed many potentialities for the improvement
in care outcomes, patient experience and access to healthcare services. AI is thought to
increase productivity and the efficiency of care delivery and allow healthcare systems to
provide more and better care to more people. Finally, it can support the faster delivery of
care, mainly by accelerating diagnosis time, and help healthcare systems manage popu-
lation health more proactively, dynamically allocating resources to where they can have
the largest impact and need. As addressed by MedTech Europe, developing AI systems
and algorithms for healthcare settings requires specific skillsets which are in short supply,
and investment in education and training of professionals involved (e.g., data scientists,
practitioners, software engineers, clinical engineers), is mandatory [18].
Ethical issues are a major hurdle to full-scale AI application use as many cases might
bring about risks such as wrong diagnosis or deviant therapy, as well as dissent among
personnel due to different opinions regarding correct AI analysis and advice. Therefore,
not only HCI issues but also human-human interaction and collaboration issues and ethical
questions to be solved and communicated among people first of all before AI can contribute
according to the full potential in health care.
5. Outlook
AI will play a significant role in future hospital health care systems. Applications
such as ML will further advance the development of processes in several fields inside the
hospital, of which we focus in medical diagnosis, logistics and care in this article. Important
obstacles remain, such as regulations, integrations to the Electronic Health Record (EHR),
standardization, medical devices certificates, training professionals, costs, updates—but
this is manageable. It is important to stress that AI applications will not replace human
clinicians but help them to concentrate on important human-related processes and to make
correct diagnoses with less analysis and decision time. This hopefully provides them with
time and focus to support patients from a specific human perspective. As a result of the
developments in computational power and algorithmic advancements, combined with
digitalization and improvements in data collection methods and storage technologies,
the healthcare sector today is supported by AI, ML and robotics as never before in the
history of medicine. Besides monitoring large-scale medical trends, these new technologies
also allow measurement of individual risks based on predictions from big data analysis.
AI has a key function in the healthcare management of the future. Research has already
proven the game changing potential of AI in various fields of healthcare, such as those
outlined in the use cases in this article. AI-based methods have been successfully developed
to address several healthcare logistics problems such as appointment planning, patient
and resources scheduling, resource utilization, and predicting demand for emergency
departments, intensive care units, or ambulances [45]. In addition, there already exist
a number of research studies which suggest that AI can perform at least as good as
humans at basic healthcare functions, such as diagnosis. Today, malignant tumors are
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spotted more successfully by algorithms than humans [46]. As a consequence of rapid
technological advancements, combined with ML’s enhanced ability to transform data into
insight, many of the medical tasks previously limited to humans are expected to be taken
on by algorithms [47]. However, there are several reasons why it will take a long time
before AI might take over comprehensive fields of activity from humans in hospitals and
healthcare: recent developments show that AI systems will not replace humans on a large
scale, but rather will support them in their efforts of patient care. Progressing into future
times, healthcare specialists can switch to tasks and job designs focusing on unique human
skills such as empathy and care. One risk within this development might be the position of
healthcare providers who are unable or refuse to work in collaboration with AI applications,
endangering their contributions and jobs. The most important obstacle regarding AI
applications in healthcare are not the capabilities or benefits of the technologies themselves,
but their applicability in medical practice. Widespread use of AI systems requires approval
by regulating institutions, integration with existing systems, sufficient standardization
with similar products, training of healthcare professionals, and solutions regarding issues
of data privacy and security. These challenges will eventually be solved, but it will take
significant time and resources [46]. The COVID-19 crisis has revealed the challenges for
healthcare systems—also for future pandemic situations. This increased attention to the
potential of AI in healthcare as one means of pandemic management and prevention. Major
challenges in responding to COVID-19, such as managing limited healthcare resources,
developing personalized treatment plans, or predicting virus spread rates, can be addressed
by recent developments in AI and ML. Wynants et al. [48] have already listed 31 prediction
models in a review of early studies of COVID-19. The prospective post-COVID-19 era in
preparation for future pandemic events will likely feature advanced healthcare solutions in
combination with operation research modeling [49]—and AI will be a crucial part of it as
outlined in this paper with 11 use case studies from European hospitals. The challenges
connected to such AI applications such as data management (HCI) have to be addressed
soon in order to prepare hospitals for future challenges, e.g., pandemic situations [50]. This
is a core challenge for health care management science and the implication for hospital
practice in order to apply the full potential of AI and ML to health care systems [51].
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